Skip to main content

Table 4 Demographic and clinical data of study participants without or with MALE

From: Serum high mobility group box-1 levels associated with cardiovascular events after lower extremity revascularization: a prospective study of a diabetic population

 

NO MALE (n = 108)

MALE (n = 93)

p value

Men/female, n

78:30

72:21

0.40

Age, years ± SD

74.1 ± 9.3

75.8 ± 8.4

0.19

Diabetes duration, years ± SD

11.4 ± 0.8

11.4 ± 0.8

0.77

BMI, Kg/m2 ± SD

26.7 ± 0.6

26.7 ± 0.7

0.63

Smoking (current), n (%)

47 (43.5)

56 (60.2)

0.02

Smoking (former), n (%)

46 (42.6)

22 (23.7)

 < 0.01

Never smoked, n (%)

16 (14.8)

15 (16.1)

0.80

Hypertension, n (%)

80 (74.1)

66 (71.0)

0.62

Hypercholesterolemia, n (%)

55 (50.9)

54 (58.1)

0.31

CAD, n (%)

51 (47.2)

41 (44.1)

0.56

CVD, n (%)

51 (47.2)

48 (51.6)

0.53

Oral antidiabetic agents, n (%)

48 (44.4)

41 (44.1)

0.95

Insulin, n (%)

73 (67.6)

74 (79.6)

0.06

ABI, ± SD

0.6 ± 0.1

0.6 ± 0.1

0.88

Rutherford II-4, n (%)

60 (55.6)

49 (52.7)

0.68

Rutherford III-5, n (%)

48 (44.4)

44 (47.3)

0.68

WIfI010, n (%)

36 (33.3)

25 (26.9)

0.32

WIfI020, n (%)

26 (24.1)

25 (26.9)

0.64

WIfI110, n (%)

26 (24.1)

23 (24.7)

0.91

WIfI120, n (%)

20 (18.5)

20 (21.5)

0.60

HbA1c, % ± SD

8.8 ± 0.7

8.9 ± 0.7

0.10

FBG, mg/dL ± SD

128.6 ± 9.8

127.1 ± 9.3

0.27

Total cholesterol, mg/dL ± SD

215.3 ± 23.1

223.0 ± 20.7

0.01

LDL cholesterol, mg/dL ± SD

111.9 ± 15.5

113.0 ± 15.4

0.61

Triglycerides, mg/dL ± SD

171.4 ± 8.3

173.8 ± 8.5

0.04

eGFR, mL/min/1.73m2 ± SD

72.5 ± 10.7

72.6 ± 10.4

0.95

HMGB-1, ng/mL ± SD

4.8 ± 2.6

7.2 ± 2.0

 < 0.01

  1. Statistical test performed with Student’s t-test or with Chi square test, when appropriate
  2. BMI, body mass index; CAD, coronary artery disease; CVD, cerebrovascular disease; ABI, ankle brachial index; WIfI, wound, ischemia, foot infection; FBG, fasting blood glucose; eGFR, estimated glomerular filtration rate; HMGB-1, high mobility group box 1